Koninklijke Philips (NYSE:PHG) Given Consensus Recommendation of “Hold” by Analysts

Koninklijke Philips (NYSE:PHG) has been assigned an average rating of “Hold” from the two brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and one has assigned a buy rating to the company.

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. raised shares of Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research note on Tuesday. BNP Paribas lowered shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Finally, UBS Group raised Koninklijke Philips from a “sell” rating to a “neutral” rating in a research note on Tuesday.

Hedge Funds Weigh In On Koninklijke Philips

A number of institutional investors have recently made changes to their positions in PHG. Capital Analysts LLC raised its holdings in shares of Koninklijke Philips by 6.3% during the 4th quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock valued at $206,000 after buying an additional 521 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its position in Koninklijke Philips by 5.7% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,374 shares of the technology company’s stock valued at $265,000 after acquiring an additional 615 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Koninklijke Philips by 3.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock worth $451,000 after acquiring an additional 696 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in shares of Koninklijke Philips by 1.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 44,746 shares of the technology company’s stock worth $892,000 after acquiring an additional 750 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Koninklijke Philips by 34.4% in the 1st quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company’s stock valued at $60,000 after purchasing an additional 770 shares in the last quarter. Institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Stock Up 26.8 %

Koninklijke Philips stock opened at $26.71 on Tuesday. The firm has a market capitalization of $24.80 billion, a price-to-earnings ratio of -46.86, a P/E/G ratio of 1.09 and a beta of 0.88. The firm has a 50 day simple moving average of $20.56 and a 200 day simple moving average of $20.99. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $29.44. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last posted its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. The business had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.47 billion. On average, analysts predict that Koninklijke Philips will post 1.53 earnings per share for the current year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.